SHANGHAI, Dec. 12, 2023 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2023 American Society of Hematology (“ASH”) Annual Meeting, the Company presented one poster with study results for zevorcabtagene autoleucel (“zevor-cel”, R&D code: CT053, an autologous CAR T-cell therapy candidate against BCMA), which include the 3-year follow-up on efficacy and safety results from the Phase I portion of Phase I/II registrational study in China (LUMMICAR-1, NCT03975907). Details are listed below:

Poster #4845: Three-Year Follow-up on Efficacy and Safety Results from Phase I LUMMICAR Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma

Zevor-cel is a fully human autologous chimeric antigen receptor (CAR) T-cell therapy product against B-cell maturation antigen (BCMA) which is being developed for the treatment of patients with relapsed or refractory multiple myeloma (R/R MM).

The LUMMICAR STUDY 1 trial is a multi-center, open-label Phase I/II clinical trial ongoing in China. The New Drug Application (NDA) in China for zevor-cel is based on the Phase I/II data from LUMMICAR STUDY 1 and is currently under review.

Herein, the Company presented the updated results with 3 years of follow-up after the last patient was infused with zevor-cel in the Phase I portion of the study. Responses were assessed by investigator per the International Myeloma Working Group (IMWG) 2016 criteria.

As of July 17, 2023, 14 participants with R/R MM, who had received at least 3 prior regimens including a proteasome inhibitor and an immunomodulatory drug (IMiD) with a median of 6 prior regimens (range: 3-11), received zevor-cel infusion. A single infusion of zevor-cel was administered 1-2 days after the completion of lymphodepletion. Three participants received 1.0×108 CAR+ T cells, and 11 participants received 1.5×108 CAR+ T cells. The median age of the cohort was 54 years (range: 34-62 years); 50.0% (7/14) of the participants had high-risk cytogenetic abnormalities, 14.3% (2/14) had extramedullary disease (EMD), and 14.3% (2/14) of the participants had Stage III disease based on International Staging System (ISS).

Overall, the safety profile of zevor-cel was manageable. There were no ≥ Grade 3 cytokine release syndrome (CRS) events. There were no immune effector cell-associated neurotoxicity syndrome (ICANS) events of any grade. Three treatment-related Grade 3 infections were observed. Three patients experienced serious adverse events (SAE) including 2 patients who had treatment-related SAEs which were pulmonary infection and tumor lysis syndrome. There were overall 2 deaths on the study; neither was related to zevor-cel.

As of July 17, 2023, the median follow-up duration was 37.7 months (range:14.8-44.2 months). The overall response rate (ORR) was 100% (14/14) with 78.6% (11/14) patients achieving a complete response (CR) or a stringent complete response (sCR); minimal residual disease (MRD) negativity was attained in all patients achieving either a CR or sCR. The median duration of response (mDOR) was 24.1 months in all patients and 26.0 months in those achieving CR or sCR. The median progression-free survival (mPFS) was 25.0 months. A total of 7 (50%) patients were in remission lasting longer than 24 months. The median overall survival (OS) was not reached, and 92.9% (13/14) of patients were still alive at month 36.

At 3-year follow up of Phase I portion of LUMMICAR-1 study in heavily pre-treated R/R MM population, zevor-cel demonstrated an encouraging safety profile with deep and durable responses consistent with the initial results.

About Zevor-cel
Zevor-cel (CT053) is a fully human, autologous BCMA CAR T-cell product candidate for the treatment of R/R MM. The New Drug Application (NDA) for zevor-cel is based on the Phase I/II data from LUMMICAR STUDY 1 in China and is currently under review. CARsgen is conducting a Phase 1b/2 LUMMICAR STUDY 2 clinical trial in North America to evaluate the safety and efficacy of zevor-cel for R/R MM.

Zevor-cel received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations from the U.S. FDA in 2019, as well as Priority Medicines (PRIME) and Orphan Medicinal Product designations from the European Medicines Agency (EMA) in 2019 and 2020, respectively. Zevor-cel also received Breakthrough Therapy designation from the NMPA in 2020.

About CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company with operations in China and the U.S. and is focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. CARsgen has established a comprehensive CAR T-cell research and development platform, encompassing target discovery, innovative CAR T-cell development, clinical trials, and commercial-scale production. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. CARsgen’s vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.

Forward-looking Statements
All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

Contact CARsgen
For more information, please visit
Public Relations:
Investor Relations: